why choose us

First received: May 31, 2023

Clinical Trial: SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed or Refractory Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: An Open-Label Phase I/II Study of SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Brief Summary: This is an open-label, phase I/II dose escalation and expansion trial.The primary objective of dose escalation phase I study is to evaluate the safety and feasibility of SHR1701 in patients with relapsed or refractory classical Hodgkin Lymphoma.The primary objective of open-label, randomized, phase II study is to assess the antitumor effect of SHR1701 alone or in combination with SHR2554 in patients with relapsed or refractory classical Hodgkin Lymphoma.

Read more